Eli Lilly and Company (NYSE:LLY) Shares Acquired by Y.D. More Investments Ltd

Key Points

• Y.D. More Investments Ltd has increased its holding in Eli Lilly and Company (NYSE:LLY) by 454.4%, purchasing an additional 777 shares to own a total of 948 shares worth $783,000.
• Wall Street analysts have mixed ratings on Eli Lilly, with 17 analysts issuing buy ratings and an average price target of $1,012.56.
• Eli Lilly announced a quarterly dividend of $1.50 per share, representing an annualized amount of $6.00 and a yield of 0.8%.

Y.D. More Investments Ltd lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 454.4% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 948 shares of the company's stock after purchasing an additional 777 shares during the period. Y.D. More Investments Ltd's holdings in Eli Lilly and Company were worth $783,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Applied Finance Capital Management LLC grew its holdings in Eli Lilly and Company by 1.4% during the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company's stock worth $660,000 after acquiring an additional 12 shares in the last quarter. Garner Asset Management Corp grew its holdings in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after acquiring an additional 12 shares in the last quarter. Tobias Financial Advisors Inc. grew its holdings in Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock worth $237,000 after acquiring an additional 12 shares in the last quarter. Redwood Investments LLC grew its holdings in Eli Lilly and Company by 0.5% during the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock worth $1,705,000 after acquiring an additional 12 shares in the last quarter. Finally, Hobbs Wealth Management LLC grew its holdings in Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after acquiring an additional 12 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

LLY has been the subject of several analyst reports. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Guggenheim upped their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a "buy" rating in a report on Friday, July 11th. Morgan Stanley restated an "overweight" rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Finally, HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $990.89.

Eli Lilly and Company Stock Performance

LLY stock traded down $15.71 on Friday, hitting $625.15. The company's stock had a trading volume of 14,089,857 shares, compared to its average volume of 4,833,475. The firm has a 50 day moving average of $774.10 and a two-hundred day moving average of $798.80. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.53. The stock has a market cap of $592.48 billion, a price-to-earnings ratio of 40.86, a price-to-earnings-growth ratio of 0.91 and a beta of 0.44. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 98.25%. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.92 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 1.0%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Insider Buying and Selling

In other news, Director Jamere Jackson acquired 200 shares of the business's stock in a transaction on Friday, August 8th. The stock was bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.